Eyeglasses that use SightGlass Vision Diffusion Optic Technology significantly reduced axial length and cycloplegic spherical equivalent refraction progression in children aged 6 to 7 years with myopia, the company announced in a press release.

The lens technology, which incorporates thousands of micro-dots that scatter light and reduce contrast on the retina, is intended to reduce myopia progression in children and has shown promising results in a recent analysis of clinical trial data. According to the release, myopia affects more than 2.5 billion people worldwide and is the leading cause of visual impairment in children.

“Young myopes can be difficult to manage for many reasons,” Andrew Sedgwick, CEO of SightGlass Vision, said in the release. “Parents and eye care professionals have traditionally had a limited number of myopia control solutions for younger children.”

According to the release, analysis of 2-year interim data from the CYPRESS clinical trial, which includes 256 children across 14 clinical trial sites in the United States and Canada, suggests that “spectacles enabled with SightGlass Vision Diffusion Optic Technology offer a promising new approach to myopia control.” Participants, who were aged 6 to 10 years when enrolled and had myopia between –0.75 D and –4.5 D, were randomized and provided lenses upon enrollment. The trial is now in its third year.